Analysts’ Opinions Are Mixed on These Healthcare Stocks: Eagle Pharmaceuticals (NASDAQ: EGRX), Agios Pharma (NASDAQ: AGIO) and ImmunoGen (NASDAQ: IMGN)


Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eagle Pharmaceuticals (NASDAQ: EGRX), Agios Pharma (NASDAQ: AGIO) and ImmunoGen (NASDAQ: IMGN).

Eagle Pharmaceuticals (NASDAQ: EGRX)

Mizuho Securities analyst Irina Rivkind Koffler reiterated a Sell rating on Eagle Pharmaceuticals (NASDAQ: EGRX) today and set a price target of $40. The company’s shares opened today at $55.95.

Rivkind Koffler noted:

“We note that Eagle applied for a unique j-code for Ryanodex in malignant hyperthermia “because no other current HCPCS code describes this single source drug.” This request was not approved because the product is used exclusively in the inpatient hospital setting. We don’t think this code was widely anticipated by investors but we view this update as a modest negative for the company because it may limit reimbursement opportunities for the drug in other settings until Eagle obtains FDA approval for new indications like exertional heat stroke (which we view as unlikely). We reiterate our Underperform rating. There is no update to our model because we don’t have any value associated with either exertional heat stroke or drug-induced hyperthermia.”

According to TipRanks.com, Koffler is a 5-star analyst with an average return of 12.0% and a 47.0% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Adamas Pharmaceuticals, and Revance Therapeutics.

Eagle Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $55.50.

See today’s analyst top recommended stocks >>

Agios Pharma (NASDAQ: AGIO)

In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Agios Pharma (NASDAQ: AGIO), with a price target of $90. The company’s shares opened today at $81.43.

According to TipRanks.com, Newman is a 5-star analyst with an average return of 15.6% and a 44.7% success rate. Newman covers the Healthcare sector, focusing on stocks such as Hutchison China MediTech Ltd, Synergy Pharmaceuticals Inc, and Aileron Therapeutics Inc.

Currently, the analyst consensus on Agios Pharma is Strong Buy and the average price target is $95.75, representing a 17.6% upside.

In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock.

ImmunoGen (NASDAQ: IMGN)

In a report released today, Boris Peaker from Cowen & Co. maintained a Hold rating on ImmunoGen (NASDAQ: IMGN). The company’s shares opened today at $10.50.

According to TipRanks.com, Peaker is a 5-star analyst with an average return of 18.0% and a 52.6% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.

ImmunoGen has an analyst consensus of Moderate Buy, with a price target consensus of $14.80.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts